Michael Johnson, MD
Urology · Saint Louis, MONPI 1770710469
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Merck at 56.4% of the total. Reporting peaked in 2023 at $60,968 and has fallen 85.6% since, to $8,768 in 2025. Among urology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $759.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$90K
- Johnson & Johnson$31K
- Intuitive Surgical$14K
- Dendreon Pharmaceuticals LLC$7K
- Siemens Medical Solutions USA, Inc.$7K
- Teleflex LLC$3K
- plus $9K from 22 others
Across 36 payments — averaging $8629.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Progenics Pharmaceuticals, Inc.$218K
- Merck$87K
- Sumitomo Pharma America, Inc.$6K
What the payments were for
- Consulting fees$19,42912%
- Speaking & faculty fees$94,20559%
- Travel & lodging$26,98217%
- Food & beverage$7,5025%
- Education$12,0468%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 83 | $90,301 |
| Johnson & Johnson | 37 | $31,027 |
| Intuitive Surgical | 9 | $13,535 |
| Dendreon Pharmaceuticals LLC | 3 | $6,580 |
| Siemens Medical Solutions USA, Inc. | 1 | $6,525 |
| Teleflex LLC | 17 | $2,719 |
| Pfizer | 2 | $2,418 |
| EDAP Technomed Inc | 5 | $2,028 |
| AstraZeneca | 3 | $1,691 |
| Urogen Pharma, Inc. | 7 | $641 |
| Procept Biorobotics Corporation | 8 | $492 |
| Boston Scientific | 6 | $348 |
| Bayer | 3 | $332 |
| Coloplast | 3 | $310 |
| Janssen Scientific Affairs, LLC | 3 | $263 |
| Histosonics, Inc. | 1 | $194 |
| Sumitomo Pharma America, Inc. | 4 | $192 |
| Calyxo, Inc. | 1 | $161 |
| Tempus AI, Inc | 1 | $100 |
| AbbVie | 4 | $60 |
| Profound Medical Corp. | 1 | $60 |
| Myovant Sciences Inc. | 2 | $56 |
| ABC Home Medical Supply, Inc. | 2 | $42 |
| Neotract Inc. | 1 | $29 |
| Axonics, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Acera Surgical, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$84,029
- Erleada$29,833
- Da Vinci Surgical System$13,516
- PROVENGE$6,564
- Ai-Rad Companion Prostate MR$6,525
- AKEEGA$4,953
- LYNPARZA$4,368
- UroLift System$1,660
- FOCAL ONE$855
- UroLift$518
- JELMYTO$427
- TITAN$221
- Barrigel$192
- CVAC Aspiration System$161
- Lumenis Pulse 120H$147
- AquaBeam Robotic System$129
- ZUSDURI$124
- Nubeqa$124
- ORGOVYX$119
- AQUABEAM SYSTEM$100
How this compares
$160,164 in reported general payments places this provider in the 95th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 13 | $5,884 |
| Tamsulosin Hcl | 118 | $915 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $402 |
| Finasteride | 44 | $381 |
| Oxybutynin Chloride | 12 | $149 |
| Ciprofloxacin Hcl | 16 | $104 |
| Oxycodone Hcl | 27 | $61 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $20 | $5,88413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 urology providers in Missouri.
Other urology in Saint Louis
- Travis BullockSaint Louis$201K
- Gurdarshan SandhuSaint Louis$101K
- Gregory McLennanSaint Louis$89K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
- Meredith MetcalfSaint Louis$26K
- Maung Htein ThuSaint Louis$22K
- Alexander ChowSaint Louis$20K
- Jonathan WeeseSaint Louis$19K
- Woodson SmelserSaint Louis$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.